2024
The Cost of Safe Injection: Insights on Nonprescription Syringe Price Variability From Systematic Secret Shopping
Blough M, Rocha A, Bratberg J, Silcox J, Bolivar D, Floyd A, Gray M, Green T. The Cost of Safe Injection: Insights on Nonprescription Syringe Price Variability From Systematic Secret Shopping. Substance Abuse 2024, 45: 201-210. PMID: 38258818, DOI: 10.1177/29767342231217831.Peer-Reviewed Original Research
2022
Impact of Network Structure on New Service Pricing
Alizamir S, Chen N, Kim S, Manshadi V. Impact of Network Structure on New Service Pricing. Mathematics Of Operations Research 2022, 47: 1999-2033. DOI: 10.1287/moor.2021.1197.Peer-Reviewed Original ResearchOptimal pricingConsumption growthFirm's optimal pricingOptimal pricing decisionsNetwork of consumersDynamic pricing problemFaster consumption growthLocal network effectsFirm profitabilityFirm benefitsFirm revenuePricing decisionsConsumer interactionsNetwork externalitiesFirmsPositive externalitiesService pricingPricing problemNetwork effectsRevenuePricingDegree of connectionProfitabilityExternalitiesConsumersHow Market Power Affects Dynamic Pricing: Evidence from Inventory Fluctuations at Car Dealerships
Israeli A, Scott-Morton F, Silva-Risso J, Zettelmeyer F. How Market Power Affects Dynamic Pricing: Evidence from Inventory Fluctuations at Car Dealerships. Management Science 2022, 68: 895-916. DOI: 10.1287/mnsc.2021.3967.Peer-Reviewed Original ResearchMarket powerTransaction pricesCeteris paribusDynamic pricingProfit marginInventory fluctuationsInventory shortageInventory levelHigher market powerLow market powerPresence of inventoriesScarcity rentsJuanjuan ZhangRetail industryCar dealershipsSelling areaAutomotive dealershipsPricesAverage carDealershipsDealersPricingShort supplyFirmsRents
2021
Business models for primary health care delivery in low- and middle-income countries: a scoping study of nine social entrepreneurs
Lokman L, Chahine T. Business models for primary health care delivery in low- and middle-income countries: a scoping study of nine social entrepreneurs. BMC Health Services Research 2021, 21: 211. PMID: 33750372, PMCID: PMC7941720, DOI: 10.1186/s12913-021-06225-6.Peer-Reviewed Original ResearchConceptsSocial enterprisesSocial entrepreneursBusiness modelsMost organizationsDifferential pricingHouse IT systemsCommon business modelSocial entrepreneurshipOrganizational impactBusiness processesRevenue streamsEnterprisesEntrepreneursPublic sectorSubscription packagesPrimary dataIT systemsOrganizationFlat rateDepth interviewsPricingSocial impactKey characteristicsPrimary health care deliveryCountries
2020
Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia
Patel KK, Isufi I, Kothari S, Davidoff AJ, Gross CP, Huntington SF. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood 2020, 136: 1946-1955. PMID: 32518952, DOI: 10.1182/blood.2020004922.Peer-Reviewed Original ResearchConceptsQuality-adjusted life yearsIncremental cost-effectiveness ratioHealth care costsFirst-line ibrutinibLifetime direct health care costsCare costsCost-effectiveness ratioParametric survival modelingUnselected older adultsDirect health care costsUS payer perspectiveCurrent pricingLife yearsFixed-duration treatmentIncremental costIncremental effectivenessPayer perspectiveHigher health care costsIbrutinib armScenario analysisMonthly costCostPricingChronic lymphocytic leukemiaMarkov modelComparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
Walensky RP, Horn T, McCann NC, Freedberg KA, Paltiel AD. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis. Annals Of Internal Medicine 2020, 172: 583-590. PMID: 32150602, PMCID: PMC7217721, DOI: 10.7326/m19-3478.Peer-Reviewed Original ResearchConceptsIncremental cost-effectiveness ratioCost-effectiveness analysisFair priceCost-effectiveness ratioBase-case analysisJustifiable priceSocietal willingnessComparative pricingHealth care sectorPricesTime horizonEnd-stage renal diseaseCases of ESRDQALYDemand PrEPCare sectorEconomic savingsHIV preexposure prophylaxisSensitivity analysisCostPreexposure prophylaxisLife effectsHorizonPricingDiscount
2019
Hospital Prices Grew Substantially Faster Than Physician Prices For Hospital-Based Care In 2007–14
Cooper Z, Craig S, Gaynor M, Harish NJ, Krumholz HM, Van Reenen J. Hospital Prices Grew Substantially Faster Than Physician Prices For Hospital-Based Care In 2007–14. Health Affairs 2019, 38: 184-189. PMID: 30715987, DOI: 10.1377/hlthaff.2018.05424.Peer-Reviewed Original ResearchConceptsPhysician pricesHospital pricesHospital-based outpatient careHealth care spendingCare spendingTypes of pricesPrice growthHospital-based outpatient servicesProvider pricesReference pricingAntitrust enforcementPricesPolicy makersPricingSpendingOutpatient careRange of optionsGrowth rateGrowthPaymentsInpatient careOutpatient servicesInsurersMakersPercentGeneric Drugs in the United States: Policies to Address Pricing and Competition
Gupta R, Shah ND, Ross JS. Generic Drugs in the United States: Policies to Address Pricing and Competition. Clinical Pharmacology & Therapeutics 2019, 105: 329-337. PMID: 30471089, PMCID: PMC6355356, DOI: 10.1002/cpt.1314.Commentaries, Editorials and LettersConceptsPrice increasesDrug pricesPatent drugsGeneric drugsBrand-name manufacturersGeneric drug applicationsGeneric competitionGeneric versionsPricesPolicy solutionsUnited StatesCompetitionPolicySource of concernPrescription drugsCostPricingMarketAgency policiesPolicymakersCompetitorsPast decadeFDA's roleShortageManufacturers
2017
Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation
Hui L, von Keudell G, Wang R, Zeidan AM, Gore SD, Ma X, Davidoff AJ, Huntington SF. Cost‐effectiveness analysis of consolidation with brentuximab vedotin for high‐risk Hodgkin lymphoma after autologous stem cell transplantation. Cancer 2017, 123: 3763-3771. PMID: 28640385, PMCID: PMC5610636, DOI: 10.1002/cncr.30818.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsIncremental cost-effectiveness ratioPrice reductionHealth care costsProbabilistic sensitivity analysesMarkov decision-analytic modelCost-effectiveness ratioIndication-specific pricingLife-time costsCare costsAutologous stem cell transplantationDecision analytic modelStandard discountingQALYBrentuximab vedotinHigher health care costsActive surveillancePricingConsolidative settingConsolidation therapyCostSensitivity analysis
2004
Salesforce design with experience-based learning
MISRA S, PINKER E, SHUMSKY R. Salesforce design with experience-based learning. IIE Transactions 2004, 36: 941-952. DOI: 10.1080/07408170490487777.Peer-Reviewed Original ResearchThe Strategic Positioning of Store Brands in Retailer–Manufacturer Negotiations
Scott Morton F, Zettelmeyer F. The Strategic Positioning of Store Brands in Retailer–Manufacturer Negotiations. Review Of Industrial Organization 2004, 24: 161-194. DOI: 10.1023/b:reio.0000033350.25229.d6.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply